.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,863,297

« Back to Dashboard

Details for Patent: 7,863,297

Title:Methods of using 4-(amino)-2-(2,6-dioxo(3-piperidly))-isoindoline-3-dione for the treatment of myelodysplastic syndromes
Abstract: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or the transplantation of blood or cells. Specific second active ingredients are capable of affecting or blood cell production. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Inventor(s): Zeldis; Jerome B. (Princeton, NJ)
Assignee: Celgene Corporation (Summit, NJ)
Filing Date:Nov 12, 2007
Application Number:11/985,032
Claims:1. A method of treating a myelodysplastic syndrome, which comprises (a) administering to a patient in need thereof about 0.1 mg per day to about 10 mg per day of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione of formula: ##STR00009## or a pharmaceutically acceptable salt, solvate or stereoisomer thereof for a period of time followed by a period of rest; and (b) repeating step (a).

2. The method of claim 1, wherein the compound is a pharmaceutically acceptable salt.

3. The method of claim 1, wherein the compound is a pharmaceutically acceptable solvate.

4. The method of claim 1, wherein the stereoisomer is an enantiomerically pure R isomer or S isomer.

5. The method of claim 1, which further comprises (c) administering a therapeutically effective amount of a second active agent for a period of time followed by a period of rest; and (d) repeating step (c).

6. The method of claim 5, wherein the second active agent is capable of improving blood cell production.

7. The method of claim 5, wherein the second active agent is a cytokine, hematopoietic growth factor, an anti-cancer agent, an antibiotic, a proteasome inhibitor, or an immunosuppressive agent.

8. The method of claim 5, wherein the second active agent is etanercept, imatinib, anti-TNF-.alpha. antibodies, infliximab, G-CSF, GM-CSF, EPO, topotecan, pentoxifylline, ciprofloxacin, irinotecan, vinblastine, dexamethasone, IL2, IL8, IL18, Ara-C, vinorelbine, isotretinoin, 13-cis-retinoic acid, arsenic trioxide, or a pharmacologically active mutant or derivative thereof.

9. The method of claim 1, wherein the myelodysplastic syndrome is refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or chronic myelomonocytic leukemia.

10. The method of claim 1, wherein the compound is administered orally.

11. The method of claim 10, wherein the compound is administered in the form of a capsule or tablet.

12. The method of claim 1, wherein the number of cycle is from one to twelve cycles.

13. The method of claim 1, the compound is administered in an amount of from about 0.1 to about 10 mg per day for 21 days every 28 days for sixteen or twenty-four weeks.

14. The method of claim 1, wherein the compound is administered in an amount of from about 0.1 mg per day to about 10 mg per day for 21 days followed by seven days of rest in a 28 days cycle.

15. The method of claim 1, wherein the compound is administered orally in an amount of 0.1 mg, 1 mg, 2 mg, 2.5 mg, 5 mg or 10 mg as a capsule per day.

16. The method of claim 1, wherein the 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione is administered.

17. The method of claim 5, wherein the second active agent is azacytidine.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc